지방간에 대한 백두구 에틸아세테이트 추출물의 억제 효과 및 기전 연구

목차 (Table of Contents)

• 서론
• 재료 및 방법
• 결과
• 고찰
• 결론
• 감사의 글
• References

참고문헌 (Reference)

1 Sato K, "Vitamin E has a beneficial effects on nonalcoholic fatty liver disease : a meta-analysis of randomized controlled trials" 31 : 323-930, 2015

2 김재은, "Tribulus terrestris Suppresses the Lipopolysaccharide-Induced Inflammatory Reaction in RAW264.7 Macrophages through Heme Oxygenase-1 Expressions" 한의병리학회 28 (28): 63-68, 2014

3 Smith BK, "Treatment of nonalcoholic fatty liver disease : role of AMPK" 311 : 730-740, 2016

4 Tolman KG, "Treatment of non-alcoholic fatty liver disease" 3 : 1153-1163, 2007

5 Heo J., "Translated Dongeuibogam" Bubinmunwha 1999

6 Li S, "The role of oxidative stress and antioxidants in liver diseases" 16 : 26087-26124, 2015

7 Griffith CM, "The role of nutritional therapy in alcoholic liver disease" 29 : 296-306, 2006

8 Pastori D, "The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease" 47 : 4-11, 2015

9 Min KJ, "The effects of oxidized low density lipoprotein (oxLDL)-induced heme oxygenase-1 on LPS-induced inflammation in RAW 264.7 macrophage cells" 24 : 1215-1221, 2012

10 Beltowski J, "Statins and modulation of oxidative stress" 15 : 61-92, 2005

11 Horton JD, "SREBPs : activators of the complete program of cholesterol and fatty acid synthesis in the liver" 109 : 1125-1131, 2002

12 Kohijima M, "SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease" 21 : 507-511, 2008

13 Braunersreuther V, "Role of cytokines and chemokines in non-alcoholic fatty liver disease" 18 : 727-735, 2012

14 Sikora JP, "Proinflammatory cytokine(IL-6, IL-8), cytokine inhibitors(IL-6sR, STNFRII)and anti-inflammatory cytokines(IL-10, IL-13)in the pathogenesis of sepsis in newborns and infants" 49 : 399-404, 2001

15 Kumar A, "Patients with nonalcoholic fatty liver disease(NAFDL)have higher oxidative stress in comparison to chronic viral hepatitis" 3 : 12-18, 2012

16 Bekkering S, "Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes" 34 : 1731-1738, 2014

17 Di Minno MN, "Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease" 18 : 5839-5847, 2012

18 Matteoni CA, "Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity" 116 : 1413-1419, 1999

19 Leamy AK, "Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease" 52 : 165-174, 2013

20 Lim DW, "Mofied SJH alleviates FFAs-induced hapatic steatosis through leptin signaling pathways" 7 : 45425-, 2017

21 Rouabhia S, "Metformin in the treatment of non-alcoholic fatty liver disease : safety, efficacy and mechanism" 8 : 343-349, 2014

22 Lee KG, "Inhibitory effects of plant-derived flavonoids and phenolic acids on malonaldehyde formation from ethyl arachidonate" 51 : 7203-7207, 2003

23 Boots AW, "Health effects of quercetin : from antioxidant to nutraceutical" 585 : 325-337, 2008

24 Sultana B, "Flavonols(kaempeferol, quercetin, myricetin)contents of selected fruits, vegetables and medicinal plants" 108 : 879-884, 2008

25 Lee DH, "Detection of anti-inflammatory agents from natural products as inhibitors of cyclooxygenase I and II" 3 : 19-28, 1997

26 Marchesini G, "Association of nonalcoholic fatty liver diseases with insulin resistance" 107 : 450-455, 1999

27 Lim DW, "Amomum cardamomum L. ethyl acetate fraction protects against carbon tetrachloride-induced liver injury via an antioxidant mechanism in rats" 16 : 155-, 2016

28 Viollet B, "Activation of AMP-activated protein kinase in the liver : a new strategy for the management of metabolic hapatic disorders" 574 : 41-53, 2006

29 Thomson DM, "AMP-activated protein kinase control of fat metabolism in skeletal muscle" 196 : 147-154, 2009

30 Murata S, "1, 8-Cineole ameliorates steatosis of pten liver specific KO mice via Akt inactivation" 16 : 12051-12063, 2015